Merck and Moderna release promising data on cancer vaccine trial
A study of a personalized vaccine combined with an existing immunotherapy found the treatment helped patients with melanoma avoid cancer recurrence. The combination trains the patient's immune system to go after cancer cells.
Moderna and Merck revealed Thursday that their personalized mRNA vaccine targeting melanoma, the most lethal form of skin cancer, reduced the likelihood of death or recurrence by 42 percent compared to traditional treatment, according to a late-stage trial. The pharmaceutical companies are already collaborating with regulatory agencies to secure approval for the vaccine.
This victory signifies a major breakthrough in melanoma treatment, and the potential of mRNA vaccines and personalized medicines to revolutionize cancer therapies is gaining momentum. Moderna CEO Stéphane Bancel stated that the company had always believed mRNA technology could enable the creation of tailored cancer treatments for each patient's unique tumor.
The trial results mark a critical milestone in realizing this vision, demonstrating the transformative impact of rethinking medicine production. These findings further validate the belief that mRNA has the capacity to fundamentally alter cancer treatment, Bancel added.
Written by urgent.news from Ars Technica's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Moderna, Merck shares fall on eagerly anticipated cancer vaccine results biopharmadive.com
- Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction cnbc.com
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term. marketwatch.com
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42% arstechnica.com
